Literature DB >> 2327756

Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function.

A Leroy1, J P Fillastre, G Humbert.   

Abstract

Lomefloxacin pharmacokinetics were investigated in 6 normal subjects and 24 uremic patients after a single oral dose of 400 mg. In subjects with normal renal function, the peak level in plasma averaged 3.5 +/- 0.9 micrograms/ml (mean +/- standard deviation) and was obtained at 1.3 +/- 0.9 h. The absorption rate constant was 3.8 +/- 1.6 h-1. The terminal half-life was 7.77 +/- 0.95 h. The apparent volume of distribution was 2.54 +/- 0.66 liters/kg. Total body and renal clearances were 259 +/- 83 and 200 +/- 55 ml/min per 1.73 m2, respectively. The percentage of the dose recovered unchanged in 48-h urine was 80.6 +/- 2.8. In uremic patients, the terminal half-life increased in relation to the degree of renal failure: from 8 h in normal subjects to 38 h in severely uremic patients (glomerular filtration rate, less than 10 ml/min). Renal insufficiency did not significantly modify the peak level in plasma, the time to peak, the apparent volume of distribution, or the nonrenal clearance of lomefloxacin. The dialysis clearance of lomefloxacin was 54 +/- 13 ml/min. Linear relationships were found between lomefloxacin pharmacokinetic parameters and glomerular filtration rate data. Dosage adjustments are necessary in uremic patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327756      PMCID: PMC171512          DOI: 10.1128/AAC.34.1.17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

3.  Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.

Authors:  P J Morrison; T G Mant; G T Norman; J Robinson; R L Kunka
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

4.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  Pharmacokinetics and tissue penetration of orally administered lomefloxacin.

Authors:  J W Stone; J M Andrews; J P Ashby; D Griggs; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

6.  Ofloxacin pharmacokinetics in renal failure.

Authors:  J P Fillastre; A Leroy; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.

Authors:  R Wise; J M Andrews; J P Ashby; R S Matthews
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of the newer antibacterial 4-quinolones.

Authors:  M Neuman
Journal:  Clin Pharmacokinet       Date:  1988-02       Impact factor: 6.447

  8 in total
  10 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  Pharmacokinetics of temafloxacin in humans after single oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 3.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

4.  The computation of biomarkers in pharmacokinetics with the aid of singular perturbation methods.

Authors:  Jie Ma; James P Keener
Journal:  J Math Biol       Date:  2018-07-28       Impact factor: 2.259

5.  Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  G R Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  Safety and efficacy of lomefloxacin versus norfloxacin in the treatment of complicated urinary tract infections.

Authors:  I M Hoepelman; W H Havinga; R A Benne; M Zwinkels; M A de Wit; H A de Hond; T A Boon; M R Visser; F W van Asbeck; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

Review 7.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

8.  Intraprostatic distribution of lomefloxacin following multiple-dose administration.

Authors:  J M Kovarik; J A de Hond; I M Hoepelman; T Boon; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 9.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

10.  What should patients do if they miss a dose of medication? A theoretical approach.

Authors:  Elijah D Counterman; Sean D Lawley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-09-10       Impact factor: 2.745

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.